Alliance A011801 (compassHER2 RD): Postneoadjuvant T-DM1 + Tucatinib/Placebo in Patients with Residual HER2-Positive Invasive Breast Cancer

Authors:

Abstract
This report describes the rationale, purpose and design of A011801 (CompassHER2 RD), an ongoing prospective, multicenter, Phase III randomized trial. Eligible patients in the United States (US) and... Lay abstract In this research study (A011801; CompassHER2 RD), patients with early stage HER2-positive breast cancer who already received treatment with chemotherapy and anti-HER2 targeted therapie...
Funding Information
  • National Institutes of Health (U10CA180821, U10CA180882, UG1CA232760, UG1CA233180, UG1CA233290, UG1CA233329, UG1CA233373)

This publication has 37 references indexed in Scilit: